Humoral and Cellular Immune Response of Herpes Simplex (gD) Candidate Vaccines From 2 Different Cell Lines

Prophylaxis Herpes Simplex Clinical Trial

Official title: Study to Compare, in Healthy HSV Seronegative and HSV Seropositive Subjects, the Humoral and Cellular Immune Response of Herpes Simplex Candidate Vaccines Containing gD From Two Different Cell Lines and Using gD-Alum as Control

Status Completed

Clinical Trial Summary

The purpose of the study is to compare, in healthy HSV seronegative and HSV seropositive subjects, the humoral and cellular immune response of herpes simplex candidate vaccines containing gD from two different cell lines and using gD-Alum as control.

Clinical Trial Description

At the time of conduct of this study, the sponsor GlaxoSmithKline was known by its former name SmithKline Beecham. ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention

Related Conditions & MeSH terms

• Herpes Simplex
• Prophylaxis Herpes Simplex

• NCT number: NCT00698490
• Study type: Interventional
• Source: GlaxoSmithKline
• Status: Completed
• Phase: Phase 1/Phase 2
• Start date: August 1995
• Completion date: January 1997